Side-by-side comparison of AI visibility scores, market position, and capabilities
Chicago Mid-Atlantic/Midwest regulated utility (NASDAQ: EXC) ~$21.6B FY2024 revenue; ComEd/PECO/BGE/Pepco/Delmarva/ACE 10.2M customers, $34.5B capex 2024-2027, Constellation spinoff 2022 competing with PSEG and Dominion.
Exelon Corporation is a Chicago, Illinois-based regulated electric and gas utility holding company — publicly traded on the NASDAQ (NASDAQ: EXC) as an S&P 500 Utilities component — serving approximately 10.2 million electric and gas customers across six regulated utilities: Commonwealth Edison (ComEd — Chicago and Northern Illinois), PECO Energy (Philadelphia and southeastern Pennsylvania), BGE (Baltimore Gas and Electric — Baltimore metro), Pepco (Washington DC and suburban Maryland), Delmarva Power (Delaware and Eastern Shore), and Atlantic City Electric (southern New Jersey) through approximately 21,000 employees. In fiscal year 2024, Exelon reported revenues of approximately $21.6 billion and adjusted EPS of $2.40, as the company managed through its first full year as a pure-play regulated utility following the February 2022 separation of Constellation Energy (the competitive nuclear generation business) as an independent public company — Exelon retaining only the regulated utility distribution and transmission subsidiaries serving Mid-Atlantic and Midwest metropolitan areas. CEO Calvin Butler (joined as CEO in November 2022) leads Exelon's strategy of executing the regulated utility capital plan: $34.5 billion in capital investment over 2024-2027 for distribution system upgrades, grid modernization, electric vehicle charging infrastructure, and regulatory compliance investments across the six utility service territories. Exelon's Mid-Atlantic service territory (Washington DC, Baltimore, Philadelphia, and Chicago) includes the densest concentration of federal government facilities, healthcare systems, and university campuses in the US — creating anchor commercial customers with high-reliability requirements that support premium rate case arguments.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.